

Subject Index

- A**
- AAPC, *see* Attenuated colorectal polyposis
Aberrant crypt foci (ACF), 72, 111
A-CAG, 53-57
Acanthosis of the oesophagus, 133
Acardia syndrome, 185, 188
Acetaldehyde, 11
ACF, 111
Achalasia, 12, 26, 30
Acid fibroblast growth factor (aFGF), 79, 82
Acinar cell carcinoma, 220, 224, 226, 241-245, 249
Acinar cell cystadenocarcinoma, 242
Acquired immunodeficiency syndrome (AIDS), 83, 139-142, 148, 154, 195
Acral keratoses, 134
ACTH, 27, 54, 78, 81, 214, 215
Adenoacanthoma, 45
Adenocarcinoma in-situ, 109
Adenocarcinoma of the OG junction, 33
Adenoid cystic carcinoma, 10, 24
Adenoma-carcinoma sequence, 72, 97, 114, 136, 234
Adenoma malignum of the uterine cervix, 75
Adenomatoid ductal hyperplasia, 227
Adenomatosis, 114, 168, 204, 211
Adenomatous hyperplasia, 158, 167, 168, 227
Adenomatous polyposis coli, 97, 116, 120, 188, *see also* APC
Adenomatous polyps, 120, 121, 124, 135, 136
Adenomucinosis, 96
Adenomyomatous hyperplasia, 211
Adenosquamous carcinoma, 10, 24, 35, 38, 45, 70, 72, 104, 105, 109, 177, 204, 209, 220, 221, 225
Adrenal adenomas, 56
Adrenocortical carcinomas, 115
Adult T-cell leukaemia/lymphoma, 250
Advanced gastric cancer, 51
AE 1, 153
AFB1, 161, 170
aFGF, 79, 82
Aflatoxin B1, 159-161, 170
AFP, *see* Alpha-fetoprotein
Aggressive angioyxoma, 154
AIB1, 228, 229
AIDS, *see* Acquired immunodeficiency syndrome
AJCC, 34, 51
Akt/PKB, 134
AKT2, 36, 228, 229
Alanine aminotransferase (ALT), 162
Albumin, 165, 200, 201
Alcohol, 11, 21, 39, 71, 106, 159-161, 185, 199
Alcohol embryopathy, 185
Aldehyde dehydrogenase, 2, 11, 106
ALK1, 88
ALK5, 228
Alkaline phosphatase (ALP), 162, 200
Alpha 1-antichymotrypsin, 187, 195, 247
Alpha 1-antitrypsin, 160, 165, 187, 201, 247, 248, 163, 184, 187 162, 163, 172, 184, 189, 200, 202, 245, 247
Alpha-1-antitrypsin deficiency, 160, 170
Alpha heavy chain disease (aHCD), 83
Alpha-catenin, 180
Alpha-fetoprotein (AFP), 162, 165, 168, 208, 241, 242, 244, 245
Alpha-irradiation, 174
Alport syndrome, 29
Amelanotic melanoma, 201
Amphiregulin, 50
Ampulla of Vater, 71, 72, 77, 205, 207, 220, 222, 237
Ampullary somatostatin cell tumour, 79
Amsterdam Criteria, 126
Amylase, 235, 237, 248
Amylin (IAPP), 226
Anal adenocarcinomas, 151, 153
Anal intraepithelial neoplasia (AIN), 150
Anal squamous intraepithelial lesion (ASIL), 150
Anal tag, 155
Anaplastic large cell lymphoma, 250
Androgenic-anabolic steroids, 196
Angiomatosis, 142
Angiomyolipoma, 158, 193
Angiosarcoma, 70, 90, 104, 142, 158, 184, 191, 192, 196, 198, 201, 216
Anisocytosis, 185
Antioxidants, 106
AP12-MLT, 86, 141
APC, 25, 36, 49, 50, 74, 98, 111, 113, 114, 116, 120, 121, 123-125, 128, 171, 188
APC germline mutation, 124
APO, 25
Apomucin, 174
Apoptosis, 15, 18, 41, 85, 116, 118, 119, 134, 149, 151, 170, 180
Appendiceal adenocarcinoma, 95, 97
Appendiceal EC-cell carcinoids, 99
Appendiceal neuroma, 102
Argentaffin, 27, 54, 55, 78, 81, 100, 138, 235
Argentaffin, serotonin-producing, carcinoids, 78
Argyrophil cells, 100
Argyrophil tumours, 54
Ashkenazi jews, 114, 230
Aspartate amino transferase (AST), 162
Aspergillus flavus, 161
Aspergillus parasiticus, 161
Astrocytoma, 123, 169
Ataxia-telangiectasia, 170, 230
ATB, 230
ATLL, 61
ATM, 230
ATM5, 49
Attenuated colorectal polyposis (AAPC), 120, 124
Atypia indefinite for intraepithelial neoplasia, 22
Atypical adenomatous hyperplasia, 168
Atypical carcinoid syndrome, 54
Atypical lymphoid infiltrate of uncertain nature, 59
Autoimmune chronic atrophic gastritis (A-CAG), 46, 53, 55
Auxilin, 133
AXIN2, 117
- B**
- B72.3, 231, 240, 242, 245
Back-to-back glands, 212
Bannayan-Riley-Ruvalcaba syndrome (BRR), 134
Barrett oesophagus, 20-26, 33, 34, 36
Basal cell carcinoma, 153, 155
Basal cell hyperplasia, 16
Basaloid carcinoma, 149
Basaloid squamous cell carcinoma, 10, 15
Basic fibroblast growth factor (bFGF), 53, 79, 82, 172
BAT26, 117, 127, 128
BAX, 50, 116-118, 128
B-cell lymphoma, 38, 60, 61, 83, 84, 86, 104, 140, 141, 190, 250
B-cell MALT lymphomas, 57
Bcl-1, 61, 85, 86, 140, 141
Bcl-2, 27, 59, 61, 86, 118, 180, 190, 217
Bcl-10, 61, 86, 141
BCL3, 36
Bcl-6, 61, 141
BDA, 179
Beckwith-Wiedeman syndrome, 185, 188, 244, 245
Ber EP4, 153, 155, 163
Beta-catenin, 111, 113, 123, 171, 180
Beta-endorphin, 138
bFGF, *see* Basic fibroblast growth factor
Bilateral talipes, 185
Bile duct adenoma (BDA), 179
Bile duct cystadenocarcinoma, 158, 182
Bile duct cystadenoma, 182
Bile reflux, 39
Biliary adenofibroma, 179
Biliary atresia, 170
Biliary cystadenoma, 211
Biliary intraepithelial neoplasia, 178

Biliary microhamartoma, 178
 Biliary papillomatosis, 158, 175, 178
 Bilroth II operation, 39
 Blastemal cells, 185
 Blood group A, 49
 Borrmann classification, 42
 Bowen disease, 150, 151
 Bowenoid papulosis, 151
 Brain tumours, 115, 126
 BRCA 1, 116
 BRCA 2, 49, 116, 228-230
 Breast cancer, 66, 67, 115, 133, 134, 228
 Budd-Chiari syndrome, 185, 191, 196
 Burkitt lymphoma, 61, 70, 83, 85, 86, 104, 139, 140, 190
 Burkitt-like/atypical Burkitt-lymphoma, 70, 86, 104
 Buschke-Lowenstein tumour, 149
 Bussey-Gardner polyposis, 120
 Byler syndrome, 170

C

C. sinensis, 173, 207
 CA 19-9, 182, 212, 222, 224, 231, 233, 235-237, 240, 247
 CA 15-3, 235
 CA 125, 224
 CagA, 40, 41, 58
 Cajal cells, 62
 Calcitonin, 27, 78
 cAMP-dependent protein kinase (PKA), 76
 CAR-5, 236
 Carbohydrate metabolism disorders, 169
 Carcinoembryonic antigen, 163, 187, 209, 232
 Carcinoembryonic antigen (CEA), 95, 100, 153, 155, 176, 178, 181, 200-202, 212, 215, 222, 224, 226, 232, 233, 235-237, 240, 242, 245, 247
 Carcinoid (well differentiated endocrine neoplasm), 10, 26, 27, 38, 45, 53-57, 70, 71, 77-82, 90, 92, 94-97, 99-102, 104, 137-139, 146, 200-202, 204, 206, 214-216, 226
 Carcinoid syndrome, 82, 137
 Carcinoma in situ, 10, 14, 15, 22, 38, 70, 94, 97, 104, 146, 150, 158, 167, 202, 204, 205, 211-214, 220, 227, 228
 Carcinomas with 'medullary' histology, 226
 Carcinomatous cirrhosis, 200, 201
 Carcinosarcoma, 14, 110, 158, 198, 209, 225
 Cardiac tumour syndrome, 191
 Caroli disease, 174
 Caspase 5, 128
 Catenins, 25
 Cathepsin D, 151
 Cathepsin-L, 118
 Cavernous haemangioma, 191, 192
 CCL, 27, 59, 217
 CD2, 88, 190
 CD3, 88, 127, 190
 CD4, 88, 190
 CD5, 27, 59, 61, 85, 86, 88, 140, 190, 217
 CD7, 88, 190
 CD8, 88, 127, 190
 CD10, 27, 59, 61, 85, 86, 140, 190, 217
 CD11c, 85, 140
 CD16, 190
 CD19, 85, 86, 140
 CD20, 27, 59, 85, 86, 140, 190, 217
 CD21, 59
 CD22, 86
 CD23, 59, 85, 86, 190
 CD30, 88, 250
 CD31, 29, 90, 142, 195, 196, 198
 CD34, 28, 29, 63, 65, 90, 142, 143, 164, 169, 185, 192, 194-196, 198, 202, 249
 CD35, 59
 CD43, 27, 59, 85, 140, 217
 CD44, 118
 CD56, 88, 190, 225
 CD68, 164, 209
 CD79a, 27, 59, 86, 190, 217
 CD95, 25
 CD103, 61, 88
 CD117, 28, 63, 65, 90
 CD138 (syndecan-1), 141
 CDH1, 49
 CDK4, 171
 CDKN2, 18, 36, 115
 CDKN2A, 17, 25, 213
 CEA, *see* Carcinoembryonic antigen
 Cell cycle control, 18
 Centrocyte-like (CCL) cell, 59
 Cellular leiomyoma, 62
 c-erbB-2, 19, 25, 36, 51, 151, 180, 213, 224, 238, 240
 Cerebellar dysplastic gangliocytoma, 133
 Children's Cancer Study Group (CCSG) classification, 187
 Cholangiocarcinoma, 159, 164, 170, 173-175, 177, 179-181, 183, 196, 201, 202
 Cholangiography, 175
 Cholangiolocellular carcinoma, 177
 Cholangitis, 174, 175, 178, 206, 207
 Cholate stasis, 169
 Choledocholithiasis, 207
 Chondrosarcoma, 209
 Choriocarcinoma, 45, 110, 201, 249
 Chorionic gonadotrophin, 78, 184, 249
 Chromoendoscopy, 12, 107
 Chromogranin A, 54, 55, 78, 81, 100, 101, 155, 187, 215, 232, 247
 Chromosomal instability, 116, 117, 128, 171
 Chronic alpha-irradiation, 174
 Chronic atrophic gastritis, 46, 53
 Chronic cholestasis, 169
 Chronic cholestatic syndromes, 170
 Chronic gastritis, 33, 40, 60
 Chronic pancreatitis, 221
 Chronic ulcerative colitis, 95
 CHRPE, *see* Congenital hypertrophy of the retinal pigment epithelium, 125
 Chymotrypsin, 224, 242, 244, 248
 Ciliated cell carcinoma, 226, 249
 CIP1, 116, 119, 171
 Cirrhosis, 160-163, 167-170, 174, 180, 190, 200, 202
 c-kit, 29, 62, 63, 90, 142, 143, 202
 c-kit mutations, 29, 63
 c-KRAS, 114, 171
 Clear cell adenocarcinoma, 204, 208

Clear cell carcinoma, 226, 249
 Cleft palate, 185
 Clonorchis sinensis, 173
 c-met, 50, 188
 c-myc, 18, 61, 86, 116, 123, 151
 c-neu, 74
 Coeliac disease, 12, 58, 72, 73, 84, 87-89
 Collagen type IV, 29, 65, 142
 Collision tumour, 35, 45, 181, 226
 Colonic EC-cell carcinoids, 138
 Colonoscopy, 107
 Colorectal carcinoma, 106, 109, 110, 112, 115, 125, 126, 132, 136, 153, 155, 199, 200, 201
 Columnar cells, 21, 33, 36, 47, 73, 133, 202, 208, 210-213, 215, 224, 226, 235
 Columnar metaplasia, 21
 Combined fetal and embryonal epithelial hepatoblastoma, 185
 Combined hepatocellular and cholangiocarcinoma, 158, 181
 Comparative genomic hybridization (CGH), 13, 29, 34, 36, 49, 63, 90, 151, 171
 Condyloma, 149, 150
 Condyloma acuminatum, 150
 Congenital hepatic fibrosis, 170, 174
 Congenital hypertrophy of the retinal pigment epithelium (CHRPE), 121
 Consumption coagulopathy, 191, 192
 Cornelia de Lange syndrome, 192
 Cowden polyps, 48
 Cowden syndrome, 132
 CpG islands, 17
 CpG sites, 36
 Crohn disease, 71-73, 83, 87, 106, 114, 137, 148, 152, 155
 Crypt cell carcinoma, 110
 CTRB, 171
 Cushing syndrome, 54, 214, 244
 Cyclin A, 118
 Cyclin D, 151, 171
 Cyclin D1, 17, 18, 61, 85, 123, 124, 140, 171, 188, 190
 Cyclin E, 240
 Cyclin-dependent kinase, 116, 171
 Cyclo-oxygenase 2, 118
 Cystadenocarcinoma, 95, 98, 182, 183, 204, 208, 211, 220, 234-236, 241
 Cystadenoma, 97, 98, 158, 182, 183, 204, 208, 211, 220, 231-234
 Cystic disease fluid protein, 153, 157, 202
 Cystothioninuria, 185
 Cytochrome P-450, 106, 161
 Cytokeratin, 44, 92, 149, 163, 176, 181, 202, 209, 224, 225, 231, 236, 238, 240, 247, 249
 Cytokeratin 7, 20, 92, 178

D

DALM, 114
 DCC (deleted in colon cancer), 36, 49, 114, 118
 D-cell, 77, 78
 DCIS, 133
 Des-gamma-carboxyprothrombin (DCP), 162
 Desmoid tumour, 120-122, 124
 Desmoplasia, 45

Diabetes mellitus, 78, 194, 221, 235
 Diffuse carcinoma, 39, 44
 Diffuse hyperplasia, 97, 112
 Diffuse large B-cell lymphoma (DLBCL), 24, 38, 39, 42, 60, 61, 70, 83, 84, 86, 104, 140, 141, 215
 DLC1 gene, 17, 18
 DNA methylation, 172
 DNA methyltransferase, 172
 DNA mismatch repair, 117, 129, 228, 229
 DNA replication errors (RER), 116
 DNMT1, 172
 Down syndrome, 185
 DPC4, 132, 228, 229, 240
 Ductal adenocarcinoma, 221, 223-227, 230, 235, 243
 Ductal papillary hyperplasia, 227
 Ductular cell hyperplasia, 227
 Dukes classification, 109
 Duodenal gastrin-cell tumours, 78
 DUPAN-2, 222, 224, 236, 240, 245
 Dye endoscopy, 47
 Dyspepsia, 41, 58
 Dysphagia, 12, 23, 26-28, 30, 34
 Dysplasia associated lesion or mass (DALM), 114
 Dysplastic gangliocytoma of the cerebellum, 132
 Dysplastic nodules, 158, 167-169

E

E2F-4, 50, 128
 E6-associated protein, 151
 E7 protein, 151
 Early gastric cancer, 41, 45, 51
 EBV *see* Epstein-Barr virus
 E-cadherin, 25, 49, 50, 116, 123, 129, 172, 180, 224
 EC-cell, 55, 79-82, 100, 137, 138
 EC-cell, serotonin-producing carcinoid, 53-56, 70, 77, 78, 80, 81, 94, 100, 104
 ECL-cell hyperplasia, 53, 54
 ECL-cell tumours, 54, 56, 82
 EGFR, *see* Epidermal growth factor receptor
 EMA, *see* Epithelial membrane antigen
 embryonal carcinoma, 45
 Embryonal rhabdomyosarcoma, 184, 216
 Embryonal sarcoma, 191, 194, 195
 Endocrine tumours, 26, 77, 78, 80, 137, 214, 249
 Endodermal sinus tumour, 45, 158
 Endogenous nitrosamine formation, 174
 Endometrial carcinoma, 126, 133
 Endoscopic mucosectomy, 108
 Endoscopic ultrasonography (EUS), 12, 23, 34, 222
 Enkephalin, 81, 138
 Enteroglucagons, 100
 Eosinophilic granuloma, 155
 Ependymoma, 154
 Epidermal cysts, 123
 Epidermal growth factor receptor (EGFR), 17, 18, 25, 36, 79, 213
 Epidermoid cysts, 120, 121

Epidermoid metaplasia, 227
 Epithelial membrane antigen (EMA), 153, 163, 215, 236, 238, 240
 Epithelioid granulomas, 152
 Epithelioid haemangioendothelioma, 158, 191, 195
 Epstein Barr virus, 61, 85, 87, 141, 174, 177, 190, 194
 Erythrocytosis, 162
 Exploratory laparotomy, 201
 Extrahepatic bile duct adenocarcinomas, 208
 Extrahepatic bile duct carcinoma, 175, 206, 214
 Extramedullary haematopoiesis (EMH), 185, 192, 193
 Extramucosal (perianal) adenocarcinoma, 152

F

Factor VIII-related antigen, 164, 192, 198
 Familial adenomatous polyposis (FAP), 48, 49, 71-74, 97, 114, 120-127, 130, 135, 170, 188
 Familial atypical multiple mole melanoma (FAMMM), 228
 Familial breast cancer, 230
 Familial multiple polyposis, 120
 Familial pancreatic cancer, 97, 120, 230
 Familial polyposis coli, *see* Familial adenomatous polyposis
 Fanconi anaemia, 170
 Fas receptor, 25
 Fecal bile acids, 106
 Fetal epithelial hepatoblastoma, 188
 Fetal hydrops, 185
 FEZ1, 18
 FGFR4, 79, 82
 FHIT, 17, 25, 36, 50
 Fibrinogen, 163, 165, 201
 Fibrocystic disease of the breast, 132-134
 Fibroepithelial polyp, 155
 Fibrolamellar HCC, 164, 165
 Fibrosarcoma, 154, 165, 177, 198
 Fibrous polyp, 155
 FldA gene, 58
 Fluorescent in situ hybridization (FISH), 86, 141
 Focal atypical epithelial hyperplasia, 227
 Focal epithelial hyperplasia, 227
 Focal liver cell dysplasia (LCD), 168
 Focal nodular hyperplasia, 158, 169, 184, 188
 Focal non-epidermolytic palmoplantar keratoderma, 12, 17
 Follicle centre cell lymphoma, 61, 250
 Follicular carcinoma, 133, 134
 Follicular lymphoma, 84, 86
 FRA3B, 25
 Free radicals, 41
 Fundic gland polyps, 48

G

G:C>A:T transition mutations, 25
 Galectin 3, 118
 Gallbladder carcinoma, 206

Gallstones, 78, 206
 Gamma-glutamyl-transpeptidase (GGT), 162
 Gangliocytic paraganglioma, 70, 77-80
 Ganglioneuromas, 142
 Ganglioneuromatosis, 216
 Ganglioneuromatous proliferation, 131
 GANT, *see* Gastrointestinal autonomic nerve tumour
 Gardner syndrome, 120, 185, 210
 Gastric adenocarcinomas, 42
 Gastric adenomas, 47, 122
 Gastric mucin MUC5AC, 136
 Gastrin, 53-56, 77-82, 202, 210, 215, 226
 Gastrin cell tumour (gastrinoma), 53-57, 70, 77-79, 214
 Gastrin-cell (G-cell) tumours, 77
 Gastritis, 40, 46
 Gastrointestinal autonomic nerve tumour (GANT), 64, 79
 Gastrointestinal hamartomas, 132, 134
 Gastrointestinal stromal tumour (GIST), 10, 28, 29, 62, 64, 65, 70, 94, 104, 142
 Gastrointestinal polyposis syndromes, 49
 Gastro-oesophageal reflux, 20, 21, 33
 G-cell (gastrin-producing) tumours, 53, 54, 77, 78
 Gelatinous carcinoma, 225
 Genetic haemochromatosis, 170
 Genetic heterogeneity, 161
 Genetic instability, 171
 Genitourinary tumours, 134
 GERD (high risk group for adenocarcinoma), 33, 34, 36
 Germline APC mutation, 115
 Germline CDH1 mutations, 49
 Germline mutations, 49, 73, 115, 123, 124, 128, 129, 132, 228, 229
 Giant (malignant) condyloma, 149
 Giant cell carcinoma, 225
 GIST, *see* Gastrointestinal stromal tumour
 Glicentin, 81, 100, 138
 Glioblastoma multiforme, 123
 Glisson capsule, 194, 196, 198
 Globoid extracellular collagen accumulations, 90
 Globular hyaline bodies, 165
 Glomus tumour, 38, 65
 GLP-1, 100, 138
 GLP-2, 100, 138
 Glucagon, 78, 81, 100, 101, 202, 248
 Glucagon-like peptide and PP/PYY-producing L-cell carcinoids, 99
 GLUT1 glucose transporter, 118
 Glutathione S-transferase, 25, 106
 Gluten sensitive enteropathy, 87
 Giant haemangioma, 193
 Glycogen, 12, 123, 165, 168, 169, 183, 185, 186, 193, 208, 231-233, 249
 Glycogen storage disease (GSD), 169
 Glycogen synthase kinase 3 β (GSK3 β), 123
 Goblet cell carcinoid (mucinous carcinoid), 94, 99-101, 204
 Goblet cell metaplasia, 178
 Goblet cell mucin MUC2, 136
 Goblet cells, 21, 36, 73, 100, 112, 113, 133, 176, 208, 212, 215

Goldenhar syndrome, 185, 188
Goseki classification, 52
Granular cell tumour (myoblastoma),
10, 28, 29, 38, 65, 154, 204, 216
Granzyme B, 88
GSD (glycogen storage disease)-associated
HCCs, 169
GSD-related adenomas, 169
GSK3b, 123
GSTP1 (glutathione S-transferase P1), 25

H

H. pylori, *see* Helicobacter pylori
Haemangi endothelioma, 142, 184, 192, 196
Haemangioma, 142, 154, 158, 169, 192, 193,
201, 202, 216
Haemangiomas, 134
Haemangiopericytoma, 154, 194
Haematemesis, 41
Haematochezia, 130
Haemochromatosis, 160, 170
Hamartoma, 75, 78, 132, 158, 184, 187, 191
HBsAg, *see* Hepatitis B surface antigen HBV,
see Hepatitis B virus
HBV X gene, 160, 170
HCC, *see* Hepatocellular carcinoma
hCG, 54, 249
HCV, *see* Hepatitis C virus
HCV genotypes, 161
HDGC, 49, 52
Helicobacter pylori, 21, 33, 34, 40-41, 46,
48, 49, 57-61, 83
Hemihypertrophy, 185
Hep Par 1 antigen, 201
Hep Par immunoreactivity, 181
Hepadnavirus, 160
Hepatitis B core antigen (HBcAg), 160
Hepatitis B surface antigen (HBsAg), 159-161,
165, 166, 168, 170, 172, 185, 190
Hepatitis B virus (HBV), 159, 160
Hepatitis C virus (HCV), 159-161, 170, 174, 190
Hepatitis D virus (HDV), 160
Hepatoblastoma, 122, 124, 158, 184-188
Hepatocellular adenoma, 158, 168-170,
184, 188
Hepatocellular carcinoma, 158-173, 175-177,
180, 181, 184, 185, 193, 199-201,
Hepatocyte growth factor, 50
Hepatocyte growth factor receptor (MET), 180
Hepatoid adenocarcinoma, 45
Hepato lithiasis, 174-176, 178, 180, 182
Hepatomegaly, 162, 190, 191, 196, 200
Hepatosplenic T-cell lymphoma, 190
HER-2/neu, 36, 228, 229
Hereditary diffuse gastric carcinoma (HDGC),
49
Hereditary haemorrhagic telangiectasia, 170
Hereditary nonpolyposis colon cancer
(HNPCC), 49, 52, 73, 97, 114, 117, 123, 126-
129, 229, 230
Hereditary pancreatitis, 221, 228, 230
Hereditary tyrosinaemia, 170
Hernia, 185, 188
Heterocyclic amines, 106

Heterozygous alpha1-antitrypsin deficiency,
185
HHV-8, *see* Human herpesvirus
HIC-1 (hypermethylated-in-cancer) tumour
suppressor gene, 172
High-frequency microsatellite instability
(MSI-H), 117
High-grade B-cell lymphomas, 57
High-grade dysplasia, 49
High-grade glandular intraepithelial
neoplasia, 70, 104
High-grade intraepithelial neoplasia, 15, 23,
114, 212, 227
High-grade lymphoma, 60
Histamine, 54
Histidine decarboxylase, 54
HIV, 29, 58, 65, 85, 86, 102, 139, 141, 147, 148,
154, 185, 190, 250
HLA, 151
HMB-45, 151, 154, 193, 201
HML-1, 88
hMLH1, 50, 73, 74, 117, 136
hMSH2, 50, 73, 74
hMSH3, 50
hMSH6, 50
HNPCC, *see* Hereditary nonpolyposis colon
cancer
Hodgkin disease, 57, 61
Horseshoe kidney, 185
Hot beverages, 11
HP, 171
HPV, *see* Human papillomavirus
HST-1, 17
HST-2, 17
Human herpesvirus (HHV-8), 8, 90, 142, 195
Human leukocyte antigens (HLAs), 151
Human papillomavirus (HPV), 11, 16, 147,
149-151, 153
5-Hydroxy-tryptophan, 54
Hypercalcaemia, 26, 162, 165, 222
Hyperchromasia, 178, 185, 195
Hypercitullinaemia, 170
Hypergastrinaemia, 53, 55, 56, 77
Hypermethylation, 25, 50, 172, 228, 229
Hyperplasia, 54, 158, 178, 210
Hyperplastic (metaplastic) polyp, 48, 94, 97,
112, 113, 135, 136
Hyperplastic nodule, 168
Hyperplastic polyposis, 135, 136
Hypertrophic osteoarthropathy, 131
Hypoalbuminemia, 132
Hypoglycaemia, 162, 185, 222
Hypokalaemia-achlor-hydria (WDHA)
syndrome, 26

I

IBD, 87, 88
ICAM1, 118
ICC, *see* Intrahepatic (peripheral) cholangio-
carcinoma
IEL, 88, 89
IGF-1 receptors, 82
IGF1R, 36
IGF2R, 128, 172

IGFRII, 50
Immunoglobulin heavy-chain (IgH), 86
Immunoproliferative small intestinal disease
(IPSID), 83, 84, 86, 139
Immunosuppression, 58
In situ carcinoma, 10, 70, 104, 146, 158, 204,
212, 220
In vitro protein synthesis (IVPS) testing, 125
Incomplete squamous metaplasia, 227
Infantile haemangi endothelioma, 158, 184,
187, 191, 192
Inflammatory Bowel disease (IBD), 83, 87, 88,
105, 113, 137, 142, 152
Inflammatory cloacogenic polyp, 155
Inflammatory polyps, 113
Inflammatory pseudotumour, 158, 191, 194
Inguinal hernia, 185
Inorganic arsenic, 196
Insulin, 78, 82, 138, 172, 199, 202, 248
Insulin-like growth factor-1 (IGF-1), 82, 199
Insulin-like growth factor-II receptor, 172
Int-2, 19
Integrin, 17, 134
Interleukin 8, 40
Interleukin-1-a, cripto, 50
International Classification of Diseases for
Oncology (ICD-O), 10, 38, 70, 94, 104, 146,
158, 204, 220
Interstitial cells of Cajal, 62, 216
Intestinal carcinoma, 42, 44
Intestinal duplication, 72
Intestinal metaplasia, 20, 21, 33-36, 40, 44,
46-48, 238
Intestinal mucin MUC4, 136
Intestinal T-cell lymphoma (ITL), 87
Intraductal papillary cholangiocarcinoma, 175
Intraductal papillary mucinous neoplasms
(IPMNs), 226, 234
Intraductal papillary neoplasms, 237
Intraductal papillary-mucinous adenoma,
220, 2252, 37, 239
Intraductal papillary-mucinous carcinoma,
220, 226, 237, 239
Intraepithelial neoplasia (dysplasia) 10, 13,
15-17, 21-23, 25, 26, 35, 38, 40, 47, 48, 70, 71,
74, 75, 95, 104, 111-114, 127, 135, 136, 146,
148-150, 153, 158, 178, 204, 209-212, 214,
227, 234, 235, 239
Intraepithelial neoplasia in Barrett oesopha-
gus, 21
Intraglandular carcinoma, 35
Intrahepatic (peripheral) cholangiocarcinoma,
158, 165, 173-180
Intrahepatic bile duct adenoma, 158
Intrahepatic metastases, 163, 166-167, 174
Intrahepatic peribiliary cysts, 179
Intramucosal carcinoma, 48
Intramucosal neoplasia, 109
Intussusception, 75, 76, 83, 130
Invasive ductal adenocarcinoma, 227
Invasive mucinous cystadenocarcinoma,
235, 236
IPSID, *see* Immunoproliferative small intes-
tinal disease
Irradiation, 106
Isosexual precocity, 185

ITL lymphomagenesis, 87, 88, 89
IVPS testing, 125

J

Japan Pancreas Society, 223, 239
Jaundice, 72, 77, 162, 174, 182, 184, 191, 192,
196, 200, 207, 211, 214, 217, 221, 231-233,
235, 237, 241, 246, 250
Jejuno-ileal EC-cell tumours, 81, 82, 137
JunD, 56
Juvenile polyposis, 73, 97, 112, 113, 130-132,
134
Juvenile polyps, 48, 113, 130, 131

K

Kaposi sarcoma, 10, 28, 29, 38, 65, 70, 90, 94,
102, 104, 142, 154, 158, 195, 204, 216
KappaB, 40
Keratin, 35, 149, 150, 152, 177, 221, 224, 248
Keratins, 65
Keratoacanthoma, 153
KIT, 28, 29, 62, 63, 65, 90, 249
KIT expression, 29
KP1, 225
KRAS (K-ras), 74, 79, 97, 101, 124, 128, 136,
179, 180, 198, 213, 214, 222, 226, 228, 229,
232, 236, 240, 243, 248, 249
Krukenberg tumour, 42, 72
K-sam, 51, 188
Kupffer cells, 164, 185, 199

L

Lactic dehydrogenase (LDH), 200
Laminin, 65, 164
Laparoscopy, 201, 230
Large B-cell lymphomas, 217
Large cell dysplasia, 168
Large cell neuroendocrine carcinoma, 55,
138, 204
Laurén classification, 43-45, 52
L-cell, glucagon-like peptide and PP/PYY pro-
ducing tumour (carcinoid), 70, 77, 80, 94,
100, 104, 137
Leiomyoblastoma, 62
Leiomyoma, 10, 28, 29, 38, 62, 65, 70, 90, 94,
104, 132, 142, 154, 204, 216
Leiomyomatosis, 28, 142
Leiomyosarcoma, 10, 28, 29, 38, 62, 63, 65, 70,
90, 92, 94, 104, 143, 154, 193, 199, 202, 204,
216
Leukaemia, 115, 133, 155, 190
Leukoplakia, 150
Lewiss blood group antigen, 49
Lhermitte-Duclos disease (LDD), 132-134
Li-Fraumeni syndrome, 49, 115
Linitis plastica, 41, 42, 66, 67, 108, 209
Lipase hypersecretion syndrome, 241,
243, 244
Lipoma, 10, 65, 70, 90, 94, 104, 134, 142
Liver cell adenoma, 158

Liver cell carcinoma, 158
Liver cirrhosis, 160-163, 167, 174
Liver fluke, 159, 173-176, 178, 180, 207
Liver transplantation, 167
LKB1, 49, 74-76, 228-230
LMP-1, 141
LOH, 17, 18, 25, 49, 56, 79, 82, 97, 114, 128,
171, 172, 188, 213
Long term survival, 74, 172, 217
Loss of heterozygosity (LOH), 79, 171, 213
Low-frequency microsatellite instability
(MSI-L), 117
Low-grade B-cell lymphomas, 61
Low-grade B-cell MALT lymphoma, 57, 59-61,
84, 140, 190, 217, 250
Low-grade dysplasia, 49
Low-grade glandular intraepithelial
neoplasia, 70, 104
Low-grade lymphomas, 57, 58, 61, 250
Lugol iodine spray, 12
Lung cancer, 66, 91, 221
Lymphangioma, 142, 154, 158, 192, 194, 216
Lymphangiomatosis, 158, 194
Lymphoblastic lymphoma, 86
Lymphoepithelioma-like carcinoma, 177
Lymphoid polyps, 113
Lymphoma, 27, 38, 57-61, 70, 83-88, 90, 102, 133,
139-141, 154, 186, 190, 199-202, 217, 250, 251
Lymphomas of mucosa-associated lymphoid
tissue (MALT), 83
Lymphoplasmacytic lymphoma, 86
Lynch syndrome, 126

M

M3SI, 236
M6P, 172
M6P/IGF2R locus, 172
Macrocephaly, 132, 134
Macrocystic serous cystadenoma, 232
Macroglossia, 185
Macroregenerative nodule, 168
Macrotrabecular hepatoblastoma, 185
Malacoplakia, 155
Male A1ATD homozygotes, 170
Malignant fibrous histiocytoma, 14, 154, 177,
193, 216
Malignant large cell neuroendocrine
carcinomas, 77
Malignant lymphoma, 94, 104, 154, 155, 204
Malignant melanoma, 30, 104, 217
Mallory hyaline bodies, 165
MALT lymphoma, 27, 58-61, 83-86, 139-141,
190, 217
Mandibular osteomas, 121
Manganese-superoxide dismutase, 118
Mannose-6-phosphate, 172
Mantle cell lymphoma (MCL), 38, 61, 70, 83,
85, 86, 104, 139-141, 217
MAP kinase signalling, 134
Marginal zone B-cell lymphoma of MALT
type, 38, 104
Mate tea, 11
MCA (mucin-like carcinoma-associated
antigen), 235
MCC, 36
MCL, 85, 86, 139-141
MDM2, 36
Meckel diverticulum, 71, 72, 80, 185, 188
Medullary carcinoma, 70, 104, 105, 110, 111,
249
Medulloblastoma, 120, 123, 124
Melaena, 130
Melan-A, 193
Melanoma, 10, 30, 66, 67, 91, 92, 102, 146,
154, 155, 193, 200, 201, 217, 230
MEN-1, 53-57, 79, 80, 82, 101, 138, 216
Menin, 56
Meningeoma, 169
Mental retardation, 134
Mesenchymal hamartoma, 184, 191
Mesenchymal tumours, 28, 29, 62, 64, 65, 83,
90, 142, 198, 249
MET, 180
Metal-storage diseases, 170
Metaplasia, 20, 21, 25, 33, 34, 36, 45-48, 71,
178, 183, 209, 210, 227, 239
Metaplastic polyposis, 135
Methylation, 17, 18, 117, 127, 136, 171, 172
5-Methylcytosine, 36
Methylenetetrahydrofolate reductase, 106
Microadenocarcinoma, 226, 242, 249
Microglandular carcinoma, 226, 249
Microinvasive carcinoma, 167
Micrometastases, 18
Microsatellite instability, 49, 74, 107, 108, 112,
116, 126-128, 136, 226, 229
Mismatch repair deficiency, 128, 129, 136
Mixed acinar-endocrine carcinoma, 220,
241, 242
Mixed acinar-endocrine-ductal carcinoma,
242
Mixed adenocarcinoma, 45
Mixed carcinoid-adenocarcinoma, 70, 94,
100, 101, 104, 204
Mixed carcinomas, 242
Mixed ductal-endocrine, 221, 226
Mixed ductal-endocrine carcinoma, 220, 224,
226
Mixed endocrine-exocrine carcinoma, 26, 27,
99, 214, 215
Mixed endocrine-exocrine carcinomas of the
appendix, 99
Mixed endocrine-exocrine neoplasms, 100
Mixed epithelial and mesenchymal hepato-
blastoma, 186
Mixed exocrine-endocrine carcinoma, 45, 55,
226
MKK4, 228, 229
MLH1, 127-129, 228-230
MLH1 germline mutation, 127
MLV12, 36
MMAC1, 132, 133
Moderately differentiated HCC, 164, 166, 170
Motilin, 81, 138
MSH2, 127-129, 228-230
MSH2 germline mutation, 127
MSH3, 128
MSH6, 128, 129
MSI, 49, 50, 52, 107-112, 116-119, 126-129, 136
MTS1, 36

- MUC1, 26, 47, 224, 240
MUC2, 26, 47, 180, 224, 238, 240
MUC3, 224
MUC5, 224
MUC5AC, 47, 240
MUC6, 47
Mucinous adenocarcinoma 24, 42-44, 71, 95, 96, 109, 111, 114, 117, 127, 177, 204, 208
Mucinous carcinoid tumour, 226
Mucinous cystadenocarcinoma, 96, 234-236, 249
Mucinous cystadenomas, 235
Mucinous cystic neoplasm (MCN), 220, 225, 226, 234-237, 239
Mucinous noncystic carcinoma, 220, 221, 225, 227, 239
Mucocutaneous melanin pigmentation, 74
Mucoepidermoid carcinoma, 10, 24, 27, 35, 177
Mucosa associated lymphoid tissue (MALT), 57
Mucosal prolapse, 113
Muir-Torre syndrome, 126, 129
Multicentric HCCs, 166
Multilayered metaplasia, 227
Multinodular goiter, 134
Multiple adenomatosis, 120
Multiple endocrine neoplasia syndrome, type 2b (MEN2b), 123, 216
Multiple hamartoma syndrome, 132
Multiple lymphomatous polyposis, 61, 85, 86, 139, 140
MYB, 228, 229
MYBL2, 36
MYC, 17, 36, 123
Myeloma, 155, 190
Myoblastoma, 63, 154
Myogenic sarcoma, 165
- N**
- N-acetyltransferases, 106
Natural killer (NK) cell lymphomas, 89
NCAM, 82
Negative for intraepithelial neoplasia, 22
Nephroblastomas, 185
NEPPK, 17
Neural adhesion molecule (NCAM), 82
Neurilemmoma, 154
Neuroblastoma, 185, 186
Neuroendocrine tumour, 155, 153, 199-201
Neurofibroma, 142, 154
Neurofibromatosis, 64, 65, 79, 128, 142, 170, 216
Neurofibromatosis type I (NF1), 65, 79
Neurokinin A, 81
Neuroma, 94, 102
Neuron specific enolase (NSE), 247
Neurotensin, 78, 81, 138
Nitric oxide (NO), 40, 41
Nitric oxide synthase, 36, 40
Nitrosamines, 11, 21, 39-41
N-nitroso compounds, 40, 174
Nodular regenerative hyperplasia (NRH), 158, 169, 184, 188
- Nodular transformation, 158
Nodule-in-nodule, 166, 170
Non ECL-cell gastric carcinoids, 54
Non-biliary cirrhosis, 174
Non-Hodgkin lymphoma, 57, 83, 85, 190, 202, 217
Non-medullary thyroid carcinoma, 132
Nonmucinous, glycogen-poor cyst-adenocarcinoma, 249
NRASL3, 36
NRH, 169
Nucleotide instability, 116
Nutrition, 11
- O**
- O. viverrini, *see* Opisthorchis viverrini
Obesity, 21
Octreotide, 81
Oesophagitis, 11, 16, 33
Oesophagogastric junction, 20, 21, 32-36, 39
Oestrogen receptor, 202
Oligocryptal adenomas, 72, 121
Oncocytic carcinoma, 249
Opisthorchiasis, 173, 174, 178
Opisthorchis viverrini, 159, 173, 180, 207
Oral contraceptive, 160, 185, 196
Ornithine decarboxylase, 118
Osteoclast-like giant cell tumours, 225, 236
Osteoporosis, 185
Osteosarcoma, 115, 209
Ovarian cancer, 67, 116
Oxidative stress, 40
Oxyntomodulin, 100
- P**
- p15, 18, 36
p16, 18, 25, 61, 86, 114, 171, 213, 228-230, 240
p16INK4, 171
p19arf, 25
p21WAF1/CIP1 cyclin-dependent kinase inhibitor, 116, 119, 171
p27Kip1, 118, 171, 240
p53 (*see also* TP53), 19, 36, 54, 61, 74, 82, 86, 114-116, 118, 119, 136, 151, 170, 180, 212, 225, 236, 238, 240, 248
Padova classification, 47
Paget cells, 150, 153, 155
Paget disease, 152, 153
Pale bodies, 165
Palmoplantar keratoses, 134
Pancolitis, 95, 106
Pancreatic carcinoma, 91, 221, 222, 228-229
Pancreatic ductal adenocarcinomas, 221
Pancreatic gastrinomas, 80
Pancreatic intraepithelial neoplasia (PanIN), 228
Pancreatic polypeptide, 54, 78, 210, 226
Pancreatic somatostatin-cell tumours, 78
Pancreatic T-cell lymphoma, 250
Pancreatoblastoma, 220, 226, 244, 245
Paneth cell rich-adenocarcinoma, 45
- Paneth cells, 21, 24, 100, 105, 111, 208, 210-212, 215, 238
Papillary adenocarcinoma, 43, 208, 216
Papillary adenoma, biliary type, 211
Papillary adenoma, intestinal type, 210
Papillary carcinoma of thyroid, 123
Papillary ductal hyperplasia, 227
Papillary hidradenoma, 153
Papillary hyperplasia, 178, 224, 227, 239
Papillary pancreatic neoplasms, 237
Papillary-cystic tumour, 246
Papillary-mucinous carcinoma, 220, 239
Papillomatosis (adenomatosis), 204, 211
Papillomatous papules, 132-134
PAR-4, 76
Paraganglioma, 216
Parietal (oxyntic) cells, 32
Parietal cell carcinoma, 45
PCNA, 18, 36, 185, 238, 240
PDGF, 82
Pectum excavatum, 185
Peliosis hepatis-like change, 164
Pen A type, 46, 51
Pen B type, 46, 51
Periapillary neoplasms, 79
Perianal adenocarcinomas, 151
Peripheral bile duct carcinoma, 158
Persistent ductus arteriosus, 185
Peutz-Jeghers syndrome, 48, 49, 70, 73-75, 97, 104, 112, 113, 138, 210, 229, 230
Peutz-Jeghers polyps, 48, 74, 75, 113
Peyer patches, 58
Pheochromocytoma, 79
Phospholipase A2, 248
Phosphatidylinositol-3,4,5-triphosphate (PIP3), 134
PI3 kinase pathway, 134
PiZ type, 170
PLA2G2A, 124
Plasmablastic lymphoma, 61
Platelet-derived growth factor (PDGF), 51, 82
Pleomorphic large cell carcinoma, 225
Plummer-Vinson syndrome, 12
PMS1 (Postmeiotic segregation 1), 128, 129
PMS2 (Postmeiotic segregation 2), 128, 129
Polymorphism, 11, 14, 50, 106, 114, 124, 171, 227
Polypoid carcinoma, 14
Polypoid type I carcinoids, 57
Polyposis syndromes, 48
Poorly differentiated adenocarcinoma, 110, 127, 176, 178
Poorly differentiated HCC, 166, 170
Poorly differentiated neuroendocrine carcinoma, 26, 27, 53, 138, 149, 215
Population-based study, 74
Porcelain gallbladder, 207
Porphyria cutanea tarda (PCT), 170
Porphyrin metabolism, 170
Positron emission tomography (PET), 200
PP cells, 78
PP/PYY immunoreactive cells, 81
PP-cell tumours, 77
Prader Willi syndrome, 185, 188

pRb, 151
 Primary gastric lymphomas, 57
 Primary hepatosplenic T-cell lymphomas, 190
 Primary liver cancer (PLC), 159
 Primary lymphoma, 139, 190
 Primary lymphoma of the colorectum, 139
 Primary lymphoma of the oesophagus, 27
 Primary pancreatic lymphomas, 250
 Primary sclerosing cholangitis (PSC), 174
 Progesterone receptors, 211, 247
 Prostaglandin, 106
 Prostatic acid phosphatase, 81, 138
 Prostatic carcinoma, 155
 Psammoma bodies, 78
 Pseudoglandular pattern, 166, 167
 Pseudolipoma, 194
 Pseudomyxoma peritonei, 95, 96, 98, 225
 Pseudorosette, 185
 Pseudosarcomatous squamous cell carcinoma, 14
 PTEN, 115, 132-134
 PTEN hamartoma tumour syndrome (PHTS), 132, 134
 PTPN1, 36
 Pulmonary arteriovenous malformations, 131
 Pylorocardiac carcinoma, 35

R

Rab11, 25, 26
 Radiation, 119, 148, 164, 221
 Ras, 97, 107, 111-113, 116, 118, 151, 179, 180
 RAS mutations, 213
 Ras proto-oncogene, 107, 111
 Rb, 17, 18
 RB1, 229
 Reactive oxygen species, 106
 Rectal carcinoids, 137
 Rectal L-cells, 138
 Recurrent pyogenic cholangitis, 174
 Reed-Sternberg-like cells, 84
 Reflux, 20, 22, 25, 33, 39, 206
 Reflux oesophagitis, 33
 Renal cell carcinoma, 165, 199, 201, 249, 251
 Replacing growth, 167
 Rhabdoid tumour, 158
 Rhabdomyoma, 154
 Rhabdomyosarcoma, 10, 28, 29, 154, 158, 186, 204, 209
 RII, 129

S

S-100, 29, 63, 65, 78, 90, 100-102, 137, 151, 154, 187, 201, 216, 232, 247
 Saccharomyces cerevisiae SNF1 kinase, 76
 Sarcoma, 28, 29, 62, 64, 90, 115, 133, 142, 143, 158, 165, 177, 186, 194, 195, 199, 201, 202, 209, 216, 236
 Sarcomatoid carcinoma, 110, 225
 Sarcomatoid HCC, 165
 Sarcomatous HCC, 165
 Sarcomatous ICC, 177
 SCC, *see* Squamous cell carcinoma

Schinzel-Geidion syndrome, 185
 Schwann cells, 79
 Schwannoma, 38, 65
 Sclerosing hepatic carcinoma, 165
 Sebaceous gland tumours, 126
 Second primary squamous cell carcinoma (SCC), 13
 Secretory phospholipase Pla2g2a, 124
 SEER data, 28, 62, 64, 71, 74, 90, 95, 98, 99, 105, 142, 160, 196, 216
 Serotonin, 54, 55, 81, 100, 101, 137, 138, 208, 210, 211, 213, 215, 226
 Serotonin-producing enterochromaffin (EC)-cell carcinoids, 80, 99
 Serous cystadenocarcinoma, 231, 233
 Serous cystadenoma, 224, 231
 Serous microcystic adenoma, 231, 233
 Serous oligocystic adenoma, 232, 233
 Serrated adenoma, 135, 136
 Serrated adenomatous polyposis, 136
 Sertoli cell tumours of the testis, 75
 Serum glutamic-oxaloacetic transaminase (SGOT), 200
 Severe ductal dysplasia, 227
 Sex cord tumours with annular tubules (SCTAT) of the ovary, 75
 Signet-ring cell carcinoma, 38, 39, 44, 67, 70, 71, 94-96, 104, 105, 109, 111, 177, 204, 208, 213, 220, 221, 225
 Signet-ring cells, 24, 43, 49, 96, 177, 215
 Signet-ring lymphoma, 44
 Situs inversus, 170
 Skeinoid fibers, 90
 Skin angiofibromas, 56
 Slow acetylation genotypes, 125
 SMAD2, 132, 229
 SMAD3, 132
 SMAD4, 74, 132
 SMAD4/DPC4 tumour suppressor gene, 132
 Small bowel adenocarcinomas, 74
 Small cell (anaplastic) carcinoma, 149
 Small cell carcinoma (poorly differentiated endocrine neoplasm), 10, 24, 26, 27, 35, 38, 45, 53-55, 70, 72, 77, 78, 80, 94, 104, 105, 117, 137, 138, 146, 149, 200-202, 204, 209, 214-216, 251
 Small cell dysplasia, 168
 Small cell undifferentiated hepatoblastoma, 186
 Small intestinal lymphomas, 83, 86
 Small lymphocytic lymphoma, 86
 Smoking, 26, 106, 147, 159, 221
 Snare polypectomy, 108
 Soft tissue sarcomas, 63, 115
 Solid pseudopapillary tumour, 220, 246, 249
 Solid-cystic tumour, 246
 Solitary fibrous tumour, 158, 191, 194
 Somatostatin, 54, 77-81, 100, 138, 202, 210, 215, 248
 Somatostatin cell tumours, 70, 77-80
 Soto syndrome, 170
 Span-1, 222, 224
 Speckled penis, 134
 Sphincter of Oddi, 80, 205, 206
 Spindle cell carcinoma, 10, 14, 15, 110
 Spindle cell lipoma, 154

Splenomegaly, 162, 196, 202
 Squamocolumnar junction, 21, 32
 Squamous cell carcinoma, 10-19, 14-16, 24-25, 30, 38, 45, 70, 104, 105, 109, 114, 146-151, 153, 155, 177, 201, 202, 204, 209
 Squamous cell dysplasia, 150
 Squamous cell papilloma, 10, 16, 153
 Squamous metaplasia, 227
 STK11, 49, 75, 76, 228-230
 Substance P, 81, 82, 100, 138
 Survivin, 118
 Sustentacular cells, 79, 100, 137, 216
 Synovial sarcoma, 29
 Systematized Nomenclature of Medicine (SNOMED), 10, 38, 70, 94, 104, 146, 158, 204, 220

T

Tachykinins, 81
 TAG72, 224, 235
 T-cell leukemia/lymphoma (ATLL), 61
 T-cell lymphoma, 27, 61, 70, 83, 87, 88, 190
 T-cell receptor gene, 190
 Telomerase, 51, 178, 180
 Tensin, 133
 Teratoma, 158, 187, 220
 Terminal hepatic venules (THV), 196
 TGF, *see* Transforming growth factor
 Thorotrast, 174, 178, 196-198
 Thymidylate synthetase, 118
 Thyroid cancer, 133
 Thyroid carcinoma, 124, 133
 TIA-1, 190
 Tissue inhibitors of metalloproteinases, 118
 Tissue-type plasminogen activator, 118
 TNF, 199
 TNM classification, 10, 13, 18, 19, 24, 38, 51, 52, 70, 72, 94, 95, 104, 109, 119, 146, 148, 158, 182, 187, 204, 205, 207, 220, 223
 Tobacco, 11, 17, 21, 39, 147, 228
 TOC, 17, 18
 Toluidine blue, 12
 Topoisomerase II alpha, 114
 TP53, 17-19, 25, 36, 49, 50, 86, 101, 114-116, 119, 124, 128, 136, 141, 160, 162, 170-172, 179, 180, 188, 198, 208, 213, 214, 216, 228, 229, 232, 240, 243
 TP53 mutations, 17, 25, 50, 114, 116, 170, 180, 188, 198
 Trabecular pattern, 100, 164-167
 Transcription-coupled repair, 129
 Transforming growth factor receptor, 50, 132, 228, 229
 Transforming growth factor, 36, 50, 53, 74, 79, 82, 185, 172
 Trichilemmoma, 128, 132-134
 Trisomy 3, 61, 86, 141, 172
 Trisomy 18, 185, 18882, 129
 Trisomy 21, 50, 188, 172
 Trypsin, 172, 224, 232, 242, 244, 248
 TSHR, 172, 363
 Tuberosus sclerosis, 193
 Tubular adenocarcinomas, 43
 Tubular adenoma, intestinal type, 210

Tubular adenoma, pyloric-gland type, 210
Tubular carcinoid, 94, 99-101, 204
Tubulo-papillary adenoma, 211
Tumour infiltrating (intra-epithelial)
 lymphocytes (TIL), 127
Tumour malformation, 191, 192
Tumour necrosis factor (TNF), 199
Turcot syndrome, 120, 123, 126, 129
Tylosis, 12, 17
Tylosis oesophageal cancer (TOC) gene, 17
Type 1a glycogen storage disease, 185, 188
Type A (insular) argentaffin carcinoid of the
 ileum, 82
Type I ECL-cell carcinoids, 53
Type II ECL-cell carcinoids, 53-56
Type III ECL-cell carcinoids, 53, 54, 57
Type IV collagen, 164

U

UEA 1, 153, 185
Ulcerative colitis, 22, 71, 83, 95, 97, 106, 114,
 137, 139, 152, 174, 206, 207
Umbilical hernia, 185
Umbilication, 201
Undifferentiated "embryonal" sarcoma, 184
Undifferentiated (anaplastic) carcinoma,
 220, 221, 225
Undifferentiated carcinoma, 10, 38, 45, 70, 94,
 104, 105, 110, 146, 158, 165, 204, 209
Undifferentiated carcinoma with osteoclast-
 like giant cells, 220, 221, 225
Unicryptal adenomas, 121
UPA, 25
Urease, 40
Urokinase, 118
Uterine leiomyomas, 132

V

VacA, 40
Vascular endothelial growth factor (VEGF),
 172
Vascular leiomyosarcoma, 201
Vasoactive intestinal peptide, 202
Verrucous (squamous) carcinoma, 10, 14, 149
Vesicular monoamine transporter type 2
 (VMAT-2), 54
VHL, *see* Von Hippel-Lindau syndrome
Villiform hyperplasia, 22
Vimentin, 165, 183, 187, 224, 225, 232, 236, 247,
 249
Vinyl chloride monomer, 196, 198
Vinyl chloride monomer (VCM), 196
Viral protein E6, 151
Virulent *cagA vacA s1a H. pylori*, 41
Von Hippel-Lindau syndrome, 114, 216,
 231, 232
Von Meyenburg complex (biliary micro-
 hamartoma), 174, 178
Von Recklinghausen disease, 79
Von Willebrand factor, 90, 196

W

WDHA, *see* Hypokalaemia-achlor-hydrria
 syndrome
Well differentiated endocrine carcinomas
 (malignant carcinoids), 215
Well differentiated endocrine neoplasm,
 26, 27, 38, 54, 70, 94, 137
Well differentiated HCC, 166
Well differentiated tubular adenocarcinomas,
 35
Western type B-cell lymphoma of MALT, 70
WGA, 78
Wilms tumour, 185
Wilson's disease, 170
Wingless/Wnt pathway, 123, 171

X

Xanthomas, 44

Y

Yolk sac tumour, 158

Z

Z line, 20, 21
ZES, 53-56, 77-79
Zinc-2-glycoprotein, 202
Zollinger-Ellison Syndrome (ZES), 53, 77, 214,
 216